MENU
+Compare
PPH
ETF ticker: NASDAQ
AS OF
Feb 3, 04:59 PM (EDT)
Price
$106.13
Change
+$12.68 (+13.57%)
Net Assets
1.18B

PPH stock forecast, quote, news & analysis

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index... Show more

Category: #Health
PPH
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for PPH with price predictions
Feb 02, 2026

Aroon Indicator for PPH shows an upward move is likely

PPH's Aroon Indicator triggered a bullish signal on February 02, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 276 similar instances where the Aroon Indicator showed a similar pattern. In of the 276 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 30, 2026. You may want to consider a long position or call options on PPH as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PPH advanced for three days, in of 346 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for PPH moved out of overbought territory on January 15, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 64 cases where PPH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for PPH turned negative on January 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PPH broke above its upper Bollinger Band on February 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), McKesson Corp (NYSE:MCK), ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Industry description

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Market Cap

The average market capitalization across the VanEck Pharmaceutical ETF ETF is 163.43B. The market cap for tickers in the group ranges from 1.97B to 934.52B. LLY holds the highest valuation in this group at 934.52B. The lowest valued company is PRGO at 1.97B.

High and low price notable news

The average weekly price growth across all stocks in the VanEck Pharmaceutical ETF ETF was 93%. For the same ETF, the average monthly price growth was 101%, and the average quarterly price growth was 149%. AZN experienced the highest price growth at 100%, while OGN experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the VanEck Pharmaceutical ETF ETF was 16%. For the same stocks of the ETF, the average monthly volume growth was 44% and the average quarterly volume growth was -20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 35
P/E Growth Rating: 57
Price Growth Rating: 40
SMR Rating: 54
Profit Risk Rating: 58
Seasonality Score: 13 (-100 ... +100)
View a ticker or compare two or three
PPH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
335 Madison Ave.19th FloorNew York
Phone
888-658-8287
Web
www.marketvectorsetfs.com